Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery

Journal of Oral and Maxillofacial Surgery

Volumn 61, Issue 9, 2003, Pages 1030-1037

  Mehlisch, Donald R ^a,b   Desjardins, Paul J ^a   Daniels, Stephen ^a   Hubbard, Richard C ^b  

^a Premier Research   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; PARECOXIB; PLACEBO; PRODRUG; VALDECOXIB;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; FEMALE; HUMAN; MALE; MOLAR TOOTH; ORAL SURGERY; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TOOTH DISEASE;

EID: 0041859551     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-2391(03)00315-X     Document Type: Article

References (37)

1. Simon LS, Weaver AL, Graham DY, et al: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 282:1921, 1999
2. Everts B, Wahrborg P, Hedner T: COX-2-specific inhibitors-The emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 19:331, 2000
3. Clemett D, Goa KL: Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59:957, 2000
4. Simon LS: Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs? Curr Opin Rheumatol 12:163, 2000
5. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial. JAMA 284:1247, 2000
6. Leese PT, Hubbard RC, Karim A, et al: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 40:124, 2000
7. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J 12:1063, 1998
8. Lipsky PE, Brooks P, Crofford LJ, et al: Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 160:913, 2000
9. Warner TD, Mitchell JA: Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121, 1999
10. Moote C: Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain. Drugs 44:14, 1992
11. Ahmad N, Grad HA, Haas DA, et al: The efficacy of nonopioid analgesics for postoperative dental pain: A meta-analysis. Anesth Prog 44:119, 1997
12. Romsing J, Walther-Larsen S: Peri-operative use of nonsteroidal anti-inflammatory drugs in children: Analgesic efficacy and bleeding. Anaesthesia 52:673, 1997
13. Sporwart K, Greer IA, McLaren M, et al: Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. Thromb Haematol 60:382, 1988
14. Hernández-Díaz S, Rodríguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093, 2000
15. Garcia-Rodríguez LS, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with nonsteroidal antiinflammatory drugs. Lancet 343:769, 1994
16. Lichtenstein DR, Syngal S, Wolfe MM: Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: The double-edged sword. Arthritis Rheum 38:5, 1995
17. Masferrer JL, Isakson PC, Seibert K: Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 25:363, 1996
18. Gillis JC, Brogden RN: Ketorolac: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 53:139, 1997
19. RuDusky BM: Severe postoperative hemorrhage attributed to single-dose parenteral ketorolac-induced coagulopathy. Angiology 51:999, 2000
20. Conrad KA, Fagon TC, Mackie MJ, et al: Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther 43:542, 1988
21. Choo V, Lewis S: Ketorolac doses reduced. Lancet 342:109, 1993
22. Lewis S: Ketorolac in Europe. Lancet 343:784, 1994
23. Talley JJ, Brown DL, Carter JS, et al: 4-[5-Methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J Med Chem 43:775, 2000
24. Karim A, Laurent A, Kuss M, et al: Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor following intramuscular administration. Anesthesiology 94:A944, 2000 (suppl)
25. Karim A, Laurent A, Qian J, et al: Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor following intravenous administration. Anesthesiology 94:A945, 2000 (suppl)
26. Karim A, Laurent A, Slater M, et al: A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 41:1111, 2001
27. Bikhazi GB, Baiwa ZH, Snabes MC, et al: Parecoxib sodium effectively treats post-laparotomy pain. Fertil Steril 76:S95, 2001 (suppl)
28. Barton SF, Langeland FF, Snabes MC, et al: Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 97:306, 2002
29. Rasmussen GL, Steckner K, Hogue C, et al: Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop 31:336, 2002
30. Desjardins PJ, Grossman EH, Kuss ME, et al: The injectable cyclooxygenase-2 specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth Analg 93:721, 2001
31. Daniels SE, Grossman EH, Kuss ME, et al: A double-blind, randomised comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 23:1018, 2001
32. Noveck RJ, Laurent A, Kuss M, et al: Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: Two randomised, controlled trials. Clin Drug Invest 21:465, 2001
33. Harris SI, Kuss M, Hubbard RC, et al: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral, cyclooxygenase-2 specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 23:1422, 2001
34. Stoltz RR, Harris SI, Kuss ME, et al: Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 97:65, 2002
35. Fricke JR, Angelocci D, Fox K, et al: Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain. J Clin Pharmacol 32:376, 1992
36. O'Hara DA, Fragen RJ, Kinzer M, et al: Ketorolac tromethamine as compared with morphine sulfate for treatment of postoperative pain. Clin Pharmacol Ther 41:556, 1987
37. Cooper SA, Beaver WT: A model to evaluate mild analgesics in oral surgery patients. Clin Pharmacol Ther 20:241, 1976